Abstract
The 5-hydroxytryptamine 5-HT 1A receptor has been the focus of considerable research effort for over a decade. However, the definitive classification of this receptor and the full characterization of its pharmacology have awaited the development of highly selective 5-HT 1A receptor antagonists. The only compounds available until recently have been either nonselective or partial 5-HT 1A receptor agonists (or a combination of both). Confusion has arisen owing to the use of different pharmacological models in examining the functional activity of 5-HT 1A receptor ligands. Several partial agonists display only antagonist activity in models of postsynaptic 5-HT 1A receptor function, whereas their agonist properties are revealed in models of presynaptic, somatodendritic 5-HT 1A autoreceptor function. In view of these considerations, the term ‘silent antagonist’ has been introduced to distinguish true 5-HT 1A receptor antagonists from partial agonists. Allan Fletcher and colleagues review the pharmacological properties of the first selective silent 5-HT 1A receptor antagonists that have been recently discovered and discuss the potential therapeutic utility of these novel compounds.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
